CN114796117A - Microemulsion foaming agent for treating psoriasis and preparation method thereof - Google Patents
Microemulsion foaming agent for treating psoriasis and preparation method thereof Download PDFInfo
- Publication number
- CN114796117A CN114796117A CN202210574875.7A CN202210574875A CN114796117A CN 114796117 A CN114796117 A CN 114796117A CN 202210574875 A CN202210574875 A CN 202210574875A CN 114796117 A CN114796117 A CN 114796117A
- Authority
- CN
- China
- Prior art keywords
- microemulsion
- foaming agent
- psoriasis
- surfactant
- oil phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Abstract
The invention discloses a microemulsion foaming agent for treating psoriasis, which comprises a surfactant, a cosurfactant, an oil phase, a water phase and a photosensitizer medicament. The invention also provides a preparation method of the microemulsion foaming agent for treating psoriasis, which comprises the following steps: 1) preparing a drug-containing micro-emulsion solution: mixing the photosensitizer medicine with the compatible oil phase or water phase, mixing the cosurfactant with the surfactant, mixing the oil phase, the surfactant mixture and the water phase according to a proportion, and stirring and mixing to form a uniform medicine-containing micro-emulsion solution; 2) the drug-containing microemulsion solution is filled into a container and is sprayed out by a pump head with a screen to form foam. The microemulsion foaming agent provided by the invention has the advantages of high efficiency, safety, simple preparation, convenience in use and comfortable use feeling.
Description
Technical Field
The invention belongs to the technical field of microemulsion foaming agents, and particularly relates to a microemulsion foaming agent for treating psoriasis and a preparation method thereof.
Background
Psoriasis is a chronic skin disease, and is clinically mainly manifested by erythema, scales and epidermal thickening, and histopathology is manifested by abnormal keratinocyte proliferation, parakeratosis, inflammatory cell infiltration and the like. The traditional Chinese medicine has complex pathogenesis, long disease course, easy relapse and difficult cure, and greatly influences the physical and psychological health of patients. Psoriasis can be classified into psoriasis vulgaris, psoriasis pustulosa, psoriasis erythrodermalis and psoriasis arthropathica according to the disease part and disease characteristics, wherein psoriasis vulgaris (also called plaque psoriasis) is the most common and accounts for 90% of the psoriasis disease rate.
For psoriasis, the keratinocyte proliferation is mainly inhibited and the immune system is regulated clinically at present through local, physical and systemic treatment and the like. Common topical preparations comprise glucocorticoid, vitamin D3 derivative, anthraquinones, emollient, cutin debonding agent, etc.; the external preparation types include cream, gel, paste, tincture, foam, etc. For example, chinese patent publication No. CN114028372A discloses an application of glutamine as an active ingredient in preparing a medicament for treating psoriasis, a medicament for treating psoriasis and a preparation method thereof, and the dosage form can be a solution, a lotion, a liniment, an ointment, a plaster, a paste or a patch. For example, Chinese patent with publication number CN113995763A discloses an application of phosphatidylethanolamine as an active ingredient in preparing psoriasis treatment medicines, the psoriasis treatment medicines and a preparation method thereof, and an application of phosphatidylethanolamine as an active ingredient in preparing the psoriasis treatment medicines, the psoriasis treatment medicines and a preparation method thereof.
The foaming agent is a preparation which is composed of a surfactant, a medicine and other components and contains bubbles dispersed in liquid, the foaming agent can be encapsulated by a pressurized container after a propellant is added to form the foaming agent by spraying, and the foaming agent can also be sprayed by a specific spray head after the container is not encapsulated by the pressurized container to form the foaming agent. The foaming agent can be classified into a water-alcohol type foaming agent, an emulsion type foaming agent, a nano-emulsion foaming agent, an oil type foaming agent, an ointment type foaming agent, a suspension type foaming agent, etc. Compared with cream and gel, the foaming agent has lower density, is easier to coat and permeate on the surface of skin with hair or skin damage, can be uniformly coated only by lower shearing force, reduces the discomfort of patients and improves the compliance of the patients. In addition, the foaming agent only needs to be quantitatively sprayed when in use, and the medicine is packaged in the container, so that the contact with the outside is reduced, and the pollution of the liquid medicine is avoided.
For intractable psoriasis such as moderate and severe psoriasis, pustular psoriasis and the like, the external medicine can not meet the treatment requirement by being simply and locally applied, and has better treatment effect by combining with physical therapy such as phototherapy and the like. Photodynamic therapy (PDT) is an emerging treatment technology in the late seventies of the twentieth century, and refers to a method for achieving a therapeutic effect by using a photosensitizer to cause cell damage and necrosis under the irradiation of laser light with a specific wavelength. At present, PDT for treating psoriasis is still in a research stage, shows good treatment effect and higher safety in preclinical, clinical trials and treatment of individual cases, has an action mechanism which is not completely clear, and is possibly related to the following mechanisms through research: PDT inhibits keratinocyte proliferation; PDT can reduce the secretion of cytokines in the inflammatory pathogenesis and change the mode of the cytokines secreted by mononuclear cells of patients with psoriasis; PDT can promote T cell apoptosis of skin damage parts of patients with psoriasis and regulate autoimmune state.
Disclosure of Invention
The invention aims to provide a microemulsion foaming agent for treating psoriasis and a preparation method thereof, and the provided microemulsion foaming agent has the advantages of high efficiency, safety, simple preparation, convenience in use and comfortable use feeling.
The invention provides the following technical scheme:
a microemulsion foaming agent comprises a surfactant, a cosurfactant, an oil phase, a water phase and a photosensitizer drug. Wherein the photosensitizer drug is soluble in the aqueous phase or the oil phase depending on the solubility of the photosensitizer drug.
The microemulsion foaming agent provided by the invention is a microemulsion foaming agent, and the microemulsion can form uniform foam after being sprayed out by a specific foam pump head, and finally forms an emulsion state after reaching the skin.
The volume ratio of the surfactant, the cosurfactant, the oil phase, the water phase and the photosensitizer medicine is (20-40): (2-5): (2-10): (20-50): (0.05-5).
Preferably, the surfactant is selected from one or more of sodium dodecyl sulfate, sorbitan laurate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene monooleate, polyoxyethylene oleyl alcohol, caprylic/capric polyethylene glycol glyceride, sucrose fatty acid ester and fatty acid glyceride.
Preferably, the cosurfactant is selected from one or more of caprylic capric polyethylene glycol glyceride, oleoyl polyoxyethylene glyceride, polyglycerol oleate, diethylene glycol monoethyl ether, propanol, butanol, pentanol, propylene glycol, oleic acid and polyglycerol-3 ester.
Preferably, the oil phase is selected from one or more of d-limonene, cyclohexane, dimethicone, cyclomethicone, lecithin, squalane, isopropyl myristate, diethylene glycol monoethyl ether, and medium chain triglycerides.
Preferably, the aqueous phase is selected from deionized water.
Preferably, the photosensitizer drug includes, but is not limited to, chlorin e6, lotalporfin, porfimer sodium, 5-aminolevulinic acid hexyl ester, temoporfin, talaporfin.
The microemulsion foaming agent provided by the invention can be used for preparing medicines for treating psoriasis vulgaris, pustule, erythrodermic and arthropathic.
The invention also provides a preparation method of the microemulsion foaming agent, which comprises the following steps:
(1) preparing a drug-containing micro-emulsion solution: mixing the photosensitizer medicine with the compatible oil phase or water phase, mixing the cosurfactant with the surfactant, mixing the oil phase, the surfactant mixture and the water phase according to the proportion, and stirring and mixing the mixture by a magnetic stirrer at a certain rotating speed to form a uniform medicine-containing micro-emulsion solution;
(2) the drug-containing microemulsion solution is filled into a container and is sprayed out by a pump head with a screen to form foam.
The microemulsion foaming agent prepared by the invention can treat various psoriasis by applying the microemulsion foaming agent on the surface of the diseased skin and combining with photodynamic therapy, compared with the foaming agent products on the market, the microemulsion foaming agent does not need to add a propellant, can form foam only by being sprayed out by a pump head containing a screen mesh, has simple and environment-friendly preparation method, and is easy for large-scale production. And the irradiation light source adopted by PDT is laser, so that the toxic and side effects of long-term application are small, and the safety is high. The design combines the local application advantage of the foaming agent and the photodynamic therapy means of the photosensitizer, and provides a novel method which is efficient, safe, simple to prepare, convenient to use and comfortable in use for treating psoriasis of ordinary type, pustule type, erythroderma type, arthropathy type and the like.
Preferably, the volume ratio of the surfactant, the cosurfactant, the oil phase, the water phase and the photosensitizer medicine in the step (1) is (20-40): (2-5): (2-10): (20-50): (0.05-5).
Preferably, the stirring speed in the step (1) is 100-1000 rpm.
Preferably, the screen pump head in the step (2) is a screen with 10-800 meshes.
The preparation environment condition of the microemulsion foaming agent is 2-8 ℃ or room temperature, and the humidity is maintained between 0% and 60%.
The microemulsion foaming agent prepared by the method also belongs to the protection scope of the invention.
Generally, compared with the prior art, the above technical solution conceived by the present invention has the following advantages:
(1) the surfactant, the cosurfactant, the oil phase and the water phase of the microemulsion foaming agent provided by the invention are all pharmaceutical excipients approved to be used in pharmacopoeia, and the microemulsion foaming agent has high safety and has an application prospect of realizing clinical transformation.
(2) The microemulsion foaming agent provided by the invention is simple and convenient in preparation method, convenient and fast in administration, easy to coat on the surface of skin with hair and scales, and high in patient compliance.
(3) The microemulsion foaming agent provided by the invention can be canned in a container with a specific pump head, pressurization is not required, a propellant is not required to be added, the microemulsion foaming agent is environment-friendly, the preparation process is simple, the production cost is low, transportation and storage are convenient, and industrialization and clinical application are facilitated.
(4) The microemulsion foaming agent provided by the invention combines the local application advantage of the foaming agent and the photodynamic treatment means of the photosensitizer, not only can be applied to the treatment of mild and moderate psoriasis, but also provides a new efficient and safe choice for the treatment of patients with moderate and severe psoriasis.
Drawings
FIG. 1 is a schematic representation of the microemulsion foaming agent of example 1.
FIG. 2 is a confocal image of a section of mouse skin after application of the microemulsion foaming agent of example 1.
FIG. 3 is a graph showing the effect of the microemulsion foam on psoriasis in example 1.
FIG. 4 is a confocal image of a section of mouse skin after the microemulsion foaming agent of example 1 is applied.
Detailed Description
The invention is further described with reference to the following specific embodiments and the accompanying drawings.
Example 1
The embodiment provides a preparation method of a microemulsion foaming agent and inspects the treatment effect of the microemulsion foaming agent on psoriasis mice, and the preparation method comprises the following steps:
1. preparing a drug-containing microemulsion solution, mixing chlorin e6 and isopropyl myristate at a ratio of 1:50 to obtain a drug-containing oil phase, mixing caprylic capric acid polyethylene glycol glyceride and polyoxyethylene fatty acid ester at a ratio of 1: 2 to obtain a mixed surfactant, mixing the medicine-containing oil phase and the mixed surfactant according to a ratio of 3: 5, stirring by a magnetic stirrer at the rotating speed of 500rpm, and dropwise adding deionized water to ensure that the volume ratio of the drug-containing oil phase, the mixed surfactant and the deionized water is 3: 5: 5, forming a uniform micro-emulsion solution a.
2. And (3) filling the micro-emulsion solution a into a container with a sieve-containing pump head, and spraying out by using a spray head to obtain foam.
3. In-vivo photodynamic therapy treatment of psoriasis in mice investigation: a plurality of Balb/c mice of about 20g are taken, hair removal cream is added into a hair shaver to remove back hair, and the mice without red and swollen injuries on the back are selected for testing after 24 hours of observation. A mouse psoriasis model was established using imiquimod cream and dosing and modeling were performed simultaneously 5 days after modeling. The method comprises the following steps:
(1) control group (Model): performing anesthesia and photographing on every morning, and applying imiquimod cream every day;
(2) smearing chlorin e6 Non-irradiated group (Ce 6-Non-irradiated): every other day, the anaesthesia photo is scored and the dehaired skin is applied with chlorin e6 solution and daily imiquimod cream;
(3) solvent-applied light group (Solvent-irradiated): depilating, grading by taking anesthetic photograph, and applying mixed solution of isopropyl myristate, polyethylene glycol caprylate/caprate and polyoxyethylene fatty acid ester to the skin for next day at 100Mw/cm 2 The dose of light is irradiated by laser for 5min for photodynamic therapy, and imiquimod cream is applied every day;
(4) chlorin e6 smeared light group (Ce 6-illummed): depilating, grading by taking anaesthesia photograph and applying dihydroporphin e6 solution to the skin of depilated skin, and applying 100Mw/cm next day 2 The light dose is irradiated by laser for 5min for PDT treatment, and imiquimod cream is applied every day.
The foam prepared by the method is shown in figure 1. After the chlorin e6 is smeared on the skin of a mouse, the skin is taken down and made into a slice, the confocal skin is shot, the skin retention capacity is examined, and the skin confocal skin observation is shown in figure 2, so that the chlorin e6 can be seen to be retained in the stratum corneum and hair follicles. The treatment effect is shown in figure 3, and the result shows that the erythema and scales of the affected skin of the mice coated with the chlorin e6 are reduced, and the burning can be avoided by reducing the light dose in a proper amount. After the treatment, the mice were sacrificed, and the affected skin of each group of mice was H & E stained, and then observed in sections, as shown in fig. 4, the thickening of the stratum corneum of the chlorin E6-applied group was reduced, and the degree of keratosis of hair follicles was weak, as compared with the Model group.
In this embodiment, chlorin e6 may be replaced or further include one or more of Rotafoil, porfimer sodium, 5-aminolevulinic acid hexyl ester, Temoporfin, and talapofin.
In this embodiment, isopropyl myristate may be substituted or further included for one or more of d-limonene, cyclohexane, dimethicone, cyclomethicone, lecithin, squalane, isopropyl myristate, diethylene glycol monoethyl ether, and medium chain triglycerides.
In this embodiment, caprylic capric polyethylene glycol glyceride may alternatively or additionally include one or more of oleoyl polyoxyethylene glyceride, polyglycerol oleate, diethylene glycol monoethyl ether, propanol, butanol, pentanol, propylene glycol, oleic acid, polyglycerol-3 ester.
In this embodiment, the polyoxyethylene fatty acid ester may be replaced or further include one or more of sodium lauryl sulfate, sorbitan laurate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene monooleate, polyoxyethylene oleyl alcohol, caprylic/capric polyethylene glycol glyceride, sucrose fatty acid ester, and fatty acid glyceride.
Example 2
The embodiment provides a preparation method of a microemulsion foaming agent and inspects the treatment effect of the microemulsion foaming agent on psoriasis mice, and the preparation method comprises the following steps:
1. preparing a drug-containing microemulsion solution, mixing talaporfin and diethylene glycol monoethyl ether in a proportion of 1: 100 to obtain a drug-containing oil phase, mixing polyglycerol oleate and polyoxyethylene sorbitan fatty acid ester in a ratio of 1:5 to obtain a mixed surfactant, mixing the medicine-containing oil phase and the mixed surfactant according to the proportion of 1: 6, stirring by a magnetic stirrer at the rotating speed of 1000rpm, and dropwise adding deionized water to ensure that the volume ratio of the drug-containing oil phase, the mixed surfactant and the deionized water is 1: 6: and 8, forming a uniform micro-emulsion solution a.
2. And (3) filling the micro-emulsion solution a into a container with a sieve-containing pump head, and spraying out by using a spray head to obtain foam.
In this embodiment, talaporfin may be replaced or further include one or more of ralaporfin, porfimer sodium, 5-aminolevulinic acid hexyl ester, temoporfin, chlorin e 6.
In this embodiment, diethylene glycol monoethyl ether may be substituted for or further include one or more of d-limonene, cyclohexane, dimethicone, cyclomethicone, lecithin, squalane, isopropyl myristate, and medium chain triglycerides.
In this embodiment, the polyglycerol oleate is replaced by or further comprises one or more of oleoyl polyoxyethylene glyceride, diethylene glycol monoethyl ether, propanol, butanol, pentanol, propylene glycol, oleic acid, and polyglycerol-3 ester.
In this embodiment, the polyoxyethylene sorbitan fatty acid ester may be replaced or further include one or more of sodium lauryl sulfate, sorbitan laurate, polyoxyethylene monooleate, polyoxyethylene oleyl alcohol, caprylic/capric polyethylene glycol glyceride, sucrose fatty acid ester, and fatty acid glyceride.
Example 3
The embodiment provides a preparation method of a microemulsion foaming agent and inspects the treatment effect of the microemulsion foaming agent on psoriasis mice, and the preparation method comprises the following steps:
1. preparing a drug-containing microemulsion solution, mixing porfimer sodium and squalane in a ratio of 1: 80 to obtain a drug-containing oil phase, mixing oleoyl polyoxyethylene glyceride and caprylic capric acid polyethylene glycol glyceride in a ratio of 2: 3 to obtain a mixed surfactant, mixing the medicine-containing oil phase and the mixed surfactant according to a ratio of 4: 15, stirring by a magnetic stirrer at the rotating speed of 800rpm, and dropwise adding deionized water to ensure that the volume ratio of the drug-containing oil phase, the mixed surfactant and the deionized water is 4: 15: 20, forming a uniform micro-emulsion solution a.
2. And (3) filling the micro-emulsion solution a into a container with a sieve-containing pump head, and spraying out by using a spray head to obtain foam.
In this embodiment, porfimer sodium may be substituted or further include one or more of ralaporphine, talaporphine, 5-aminolevulinic acid, hexyl 5-aminolevulinate, temoporfin, chlorin e 6.
In this example, squalane may be replaced or further include one or more of d-limonene, cyclohexane, dimethicone, cyclomethicone, lecithin, isopropyl myristate, diethylene glycol monoethyl ether, and medium chain triglycerides.
In this embodiment, the oleoyl polyoxyethylene glyceride may alternatively or additionally include one or more of caprylic capric polyethylene glycol glyceride, polyglycerol oleate, diethylene glycol monoethyl ether, propanol, butanol, pentanol and propylene glycol, oleic acid, polyglycerol-3 ester.
In this embodiment, the caprylic capric acid polyethylene glycol glyceride may alternatively or additionally include one or more of sodium lauryl sulfate, sorbitan laurate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene monooleate, polyoxyethylene oleyl alcohol, sucrose fatty acid ester, and fatty acid glyceride.
Claims (10)
1. A microemulsion foaming agent for treating psoriasis, which is characterized by comprising a surfactant, a cosurfactant, an oil phase, a water phase and a photosensitizer medicament.
2. A microemulsion foaming agent for treating psoriasis according to claim 1 wherein the surfactant in the microemulsion foaming agent is selected from one or more of sodium lauryl sulfate, sorbitan laurate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene monooleate, polyoxyethylene oleyl alcohol, caprylic capric polyethylene glycol glyceride, sucrose fatty acid ester, fatty acid glyceride; the cosurfactant is one or more of caprylic/capric polyethylene glycol glyceride, oleoyl polyoxyethylene glyceride, polyglycerol oleate, diethylene glycol monoethyl ether, propanol, butanol, pentanol, propylene glycol, oleic acid and polyglycerol-3 ester.
3. A microemulsion foaming agent for use in the treatment of psoriasis according to claim 1 wherein the oil phase is selected from one or more of d-limonene, cyclohexane, dimethicone, cyclomethicone, lecithin, squalane, isopropyl myristate, diethylene glycol monoethyl ether, medium chain triglycerides; the aqueous phase is selected from deionized water.
4. A microemulsion foaming agent for use in the treatment of psoriasis according to claim 1 wherein the photosensitizer drug is selected from one or more of chlorin e6, lotalporfin, porfimer sodium, 5-aminolevulinic acid hexyl ester, temoporfin, talaporfin.
5. A microemulsion foaming agent for the treatment of psoriasis according to claim 1 wherein in the microemulsion foaming agent: the volume ratio of the surfactant to the cosurfactant to the oil phase to the water phase to the photosensitizer is (20-40): (2-5): (2-10): (20-50): (0.05-5).
6. A microemulsion foaming agent for use in the treatment of psoriasis according to claims 1 to 5 wherein the psoriasis comprises psoriasis vulgaris, pustular, erythrodermic and arthropathic types.
7. A method of preparing a microemulsion foaming agent for the treatment of psoriasis according to any one of claims 1 to 6, which comprises the following steps:
1) preparing a drug-containing micro-emulsion solution: mixing the photosensitizer medicine with the compatible oil phase or water phase, mixing the cosurfactant with the surfactant, mixing the oil phase, the surfactant mixture and the water phase according to a proportion, and stirring and mixing to form a uniform medicine-containing micro-emulsion solution;
2) the drug-containing microemulsion solution is filled into a container and is sprayed out by a pump head with a screen to form foam.
8. The preparation method of microemulsion foaming agent for treating psoriasis according to claim 7, wherein in the step 1), the volume ratio of the surfactant, the cosurfactant, the oil phase, the water phase and the photosensitizer medicine is (20-40): (2-5): (2-10): (20-50): (0.05-5).
9. The preparation method of the microemulsion foaming agent for treating psoriasis according to claim 7, wherein in the step 1), the stirring speed is 100-1000 rpm.
10. The method for preparing a microemulsion foaming agent for treating psoriasis according to claim 7, wherein in the step 2), the screen-containing pump head is a 10-800 mesh screen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210574875.7A CN114796117A (en) | 2022-05-24 | 2022-05-24 | Microemulsion foaming agent for treating psoriasis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210574875.7A CN114796117A (en) | 2022-05-24 | 2022-05-24 | Microemulsion foaming agent for treating psoriasis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114796117A true CN114796117A (en) | 2022-07-29 |
Family
ID=82516397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210574875.7A Pending CN114796117A (en) | 2022-05-24 | 2022-05-24 | Microemulsion foaming agent for treating psoriasis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114796117A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206155A1 (en) * | 2006-11-14 | 2008-08-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
| US20100221194A1 (en) * | 2009-02-25 | 2010-09-02 | Loupenok Leon | Topical foam composition |
| US20110045037A1 (en) * | 2007-11-30 | 2011-02-24 | Foamix Ltd. | Foam containing benzoyl peroxide |
| JP2018030874A (en) * | 2017-10-04 | 2018-03-01 | アナプラシ ファーマシューティカルズ エルエルシー | Aerosol, mousse, or foam composition for treating psoriasis |
| US20210060018A1 (en) * | 2018-01-09 | 2021-03-04 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
-
2022
- 2022-05-24 CN CN202210574875.7A patent/CN114796117A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206155A1 (en) * | 2006-11-14 | 2008-08-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
| US20110045037A1 (en) * | 2007-11-30 | 2011-02-24 | Foamix Ltd. | Foam containing benzoyl peroxide |
| US20100221194A1 (en) * | 2009-02-25 | 2010-09-02 | Loupenok Leon | Topical foam composition |
| CN102438590A (en) * | 2009-02-25 | 2012-05-02 | 施泰福研究澳大利亚有限公司 | Topical foam composition |
| JP2018030874A (en) * | 2017-10-04 | 2018-03-01 | アナプラシ ファーマシューティカルズ エルエルシー | Aerosol, mousse, or foam composition for treating psoriasis |
| US20210060018A1 (en) * | 2018-01-09 | 2021-03-04 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
Non-Patent Citations (2)
| Title |
|---|
| 何秀娟 等: "光动力疗法治疗银屑病的光敏剂的研究进展", 《重庆医学》 * |
| 张福荣等: "二丙酸倍他米松微乳泡沫剂的体外透皮考察", 《中国医药工业杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2602107T3 (en) | Nanoemulsion | |
| DK2498783T3 (en) | COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH | |
| US20090324705A1 (en) | Phytonutrient compositions for topical use | |
| KR101791277B1 (en) | Dermatologic and cosmetic compositions | |
| JP2009545587A (en) | Nanoliposomes using esterified lecithin, method for producing the same, and composition for preventing or treating skin diseases comprising the same | |
| CN111166760A (en) | composition of beta-nicotinamide mononucleotide or precursor thereof, preparation method and application | |
| CN101247816A (en) | Molecular complex comprising arbutine, ascorbic acid, oleuropeina or its derivatives thereof and related uses in medical field | |
| JP2011513501A (en) | Vitamin K analog formulation for topical use | |
| US20050137164A1 (en) | Diclofenac compositions for the treatment of skin disorders | |
| KR20130020742A (en) | Hair follicle targeting compositions | |
| CN101396344A (en) | Paeonol microemulsion preparation and preparation method thereof | |
| KR101443180B1 (en) | Novel Drug Delivery System for Percutaneous Absorption, Composition for External Preparation Preventing Hair Loss, and Cosmetics Using the Same | |
| CN103405385B (en) | A kind of temozolomide's intravenous injection fatty breast and preparation method thereof | |
| CN104800150A (en) | Minoxidil cream and preparation method thereof | |
| CN108283620A (en) | A kind of local medicine composition of inhibitors of phosphodiesterase-4 and preparation method thereof | |
| CN111195230B (en) | Method for preparing flexible liposome | |
| CN101129378A (en) | Medicament spraying agent used for accelerating growth of hair | |
| KR101892079B1 (en) | Composition for improving acnes and kit for improving acnes containing the same | |
| CN109731101A (en) | A kind of photosensitive medicament patch and preparation method | |
| CN114796117A (en) | Microemulsion foaming agent for treating psoriasis and preparation method thereof | |
| Gupta et al. | Localized topical drug delivery systems for skin cancer: Current approaches and future prospects | |
| CN103417966B (en) | Hydrochloric acid aminolevulinic acid liniment and preparation technology thereof | |
| KR20150119244A (en) | Topical composition for stimulating epidermis and dermis layers of the skin | |
| KR100542788B1 (en) | Methods for treating acne using ALA with cationic liposome | |
| ES2214066T3 (en) | PREPARATION OF KHELLINA FOR THE TOPICAL THERAPY OF PSORIASIS, ITS SUBTIPOS, SPECIAL FORMS, AS WELL AS THE TOPIC THERAPY OF ECZEMAS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |